AbbVie Q3 EPS $3.00 adjusted (+1.7%), revenue $14.46B (+3.8%); raises 2024 guidance, increases dividend 5.8%

AbbVie Inc.

2024-Q3 EPS reported $2.41 revenue$41,232,000,000

Adjusted diluted EPS $3.00, up 1.7% YoY; GAAP EPS $0.88, down 12.0%.
Revenue $14.460B, +3.8% reported (+4.9% operational); Immunology $7.046B (+3.9%) led by Skyrizi (+50.8%) and Rinvoq (+45.3%).
Raises 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87.
Increases quarterly dividend 5.8% to $1.64/share, payable Feb 14, 2025 to holders of record Jan 15, 2025.
Completed acquisition of Cerevel, adding pipeline of complementary neuroscience assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.